• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Leishmaniasis project launched in Eastern Africa to improve patient access to treatments

The project will contribute towards the World Health Organization Neglected Tropical Diseases roadmap targets for the control and elimination of visceral leishmaniasis

Home > Press releases

Leishmaniasis project launched in Eastern Africa to improve patient access to treatments

The project will contribute towards the World Health Organization Neglected Tropical Diseases roadmap targets for the control and elimination of visceral leishmaniasis

Patient speaking with two doctors
Nairobi, Kenya — 15 Nov 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

The Drugs for Neglected Diseases initiative (DNDi) and its partners have launched a three-year project known as LeishAccess that seeks to promote access to treatments for leishmaniasis patients. The project was launched at a community clinical trial results dissemination meeting in Kacheliba, West Pokot, Northwestern Kenya.

‘This project will transform the lives of people with leishmaniasis. LeishAccess will address the access challenges which are inhibiting progress towards the elimination of this deeply neglected and deadly disease,’ said Dr Fabiana Alves, Director of Neglected Tropical Diseases – Leishmaniasis and Mycetoma at DNDi. 

LeishAccess will increase the use of optimal diagnostics and treatment combinations to treat visceral leishmaniasis (VL), VL/HIV co-infection, and post-kala-azar dermal leishmaniasis (PKDL), a common complication that appears after visceral leishmaniasis treatment. The project will also improve access to the treatment of uncomplicated cutaneous leishmaniasis cases with local thermotherapy and conduct operational research to improve access to VL diagnosis and treatment. 

‘The project aims to strengthen access to care, contributing to the global NTD Roadmap target for the control and elimination of visceral leishmaniasis and control of cutaneous leishmaniasis as a public health problem by 2030 across Eastern Africa,’ said Rebecca M. Coulborn, Epidemiologist at Epicentre/Médecins Sans Frontières, which is part of the LeishAccess project.

Leishmaniasis is the largest parasitic killers after malaria. There are three main forms of leishmaniases: visceral (also known as kala-azar), cutaneous (the most common), and mucocutaneous. The visceral form is the most severe and is fatal if left untreated. There are 50,000 to 90,000 new visceral leishmaniasis cases annually, with the highest number of cases reported in Eastern African countries: Eritrea, Ethiopia, Kenya, Somalia, South Sudan, Sudan, and Uganda. The disease mostly affects people in resource-limited settings, in arid and semi-arid areas. Half of them are children under 15. Leishmaniasis is also a climate-sensitive disease: rising temperatures could affect the pathogen-carrying vectors and worsen its impact. 

Since 2003, DNDi has mobilized its partners to find new treatments for leishmaniasis. In Eastern Africa, research conducted by DNDi and its partners has demonstrated the effectiveness of three combination treatments in treating the disease, including for visceral leishmaniasis patients living with HIV. Clinical trials for new, promising, all-oral treatments will begin in the coming months.  

Despite progress made so far, an estimated 50% of patients still do not have access to appropriate diagnosis and treatment. A wide range of obstacles stands in the way to access: change of treatment guidelines usually takes a long time; medicines may be unaffordable for patients and health systems; production is usually insufficient and often depends on a single manufacturer; diagnosis and treatment may be unavailable where patients seek care; and at times clinicians may not be adequately trained in their use. 

Other challenges also contribute to poor access, such as political instability; poor infrastructure in the visceral leishmaniasis treatment facilities; a disruptive supply chain and hyperinflation; insufficient financial resources for care-seeking (even if visceral leishmaniasis diagnostics and treatment are free, patients must pay other healthcare fees and associated costs related to the cascade of care); limited community awareness; and population movements such as nomadic practices, migratory work, conflict, and famine.  

It is to respond to these challenges that DNDi initiated LeishAccess, which is implemented by a consortium of experts and key health institutions in collaboration with the Ministries of Health of Ethiopia, Kenya, South Sudan, Sudan and Uganda.  

‘This project is improving access to vital optimal and affordable treatments for leishmaniasis patients in Eastern Africa. Our first step is to develop, in collaboration with stakeholders, country-specific work plans that respond to the needs of the public health systems in Ethiopia, Kenya, Uganda, Sudan and South Sudan. Driving policy change is essential in ensuring patients quickly benefit from innovation from clinical research,’ said Simon Bolo, Head of Leishmaniasis Access, DNDi. 

This project is part of the EDCTP2 programme supported by the European Union (grant number RIA2020S-3301-LeishAccess), and funding from Médecins Sans Frontières (MSF), Medicor Foundation, Swiss Agency for Development and Cooperation (SDC), Takeda Pharmaceutical Company Limited and UK aid.

Advocacy initiatives through community and stakeholder engagement for policy change are ongoing. The community dissemination meeting in Kacheliba is one such step taken to share the results of one of the new treatments that proved to be effective in treating visceral leishmaniasis. 

The project will end in July 2024. Its objective is to achieve a 60% reduction in morbidity and mortality leishmaniasis cases by 2025. Some of the key anticipated results will include a strengthened supply chain management of leishmaniasis drugs, improved disease surveillance and operational research, epidemic preparedness response, improved case management, policy advocacy and strengthened coordination, partnership, and resource mobilization. 

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 cases in Africa. Since its inception in 2003, DNDi has delivered twelve new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org  

About the LeishAccess project 

LeishAccess Consortium Logo

The LeishAccess is a three-year project that seeks to improve access to care for leishmaniasis patients, including vulnerable groups, for the various forms of the disease (visceral leishmaniasis, cutaneous leishmaniasis, PKDL, and VL/HIV). It is being implemented by a consortium made up of experts and key health institutions leading access within Ethiopia, Kenya, South Sudan, Sudan, and Uganda.  The implementing partners include Armauer Hansen Research Institute (AHRI), Ethiopia; Carlos III Health Institute (ISCIII), Spain; Association Epicentre, France; Institute of Endemic Diseases (IEND), Sudan; FIND, the global alliance for diagnostics, Kenya; Makerere University, Uganda; Médecins Sans Frontières (MSF) Amsterdam, Netherlands; and University of Gondar, Ethiopia. dndi.org/leishaccess

Media contact

Linet Otieno (DNDi, Nairobi) 
latieno@dndi.org 
+254 705 639 909 

Frédéric Ojardias (DNDi, Geneva)  
fojardias@dndi.org   
+41 79 431 62 16

Ilan Moss (DNDi, New York)  
imoss@dndi.org   
+1 646 266 5216 

Photo credit: Sydelle Willow Smith – EDCTP

Registration & access Cutaneous leishmaniasis Visceral leishmaniasis

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo